Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder

April 21, 2011 By Bio-Medicine.Org

BRANFORD, Conn., April 21, 2011 /PRNewswire/ — Marinus
Pharmaceuticals, Inc., the leader in the development of
neurosteroids for central nervous system disorders, today announced
commencement of a proof-of-concept clinical trial of its lead
candidate ganaxolone for the treatment of posttraumatic stress
disorder (PTSD). Ganaxolone modulates inhibitory GABA-A receptors,
possibly at a specific neurosteroid recognition site. Neurosteroid
levels have been implicated in both the severity and treatment
outcome in PTSD patients.

“This trial will test the hypothesis that a neurosteroid analog
of allopregnanolone will be beneficial in the treatment of PTSD and
augment our existing safety database for ganaxolone in humans,”
stated Gail Farfel, Ph.D., Chief Development and Regulatory Officer
of Marinus. “Achieving full remission of PTSD symptoms is difficult
with current treatments for PTSD.  New options that can
increase efficacy are needed for the growing population of PTSD
patients worldwide.”

This randomized, double-blind, placebo-controlled clinical trial
is being conducted by the INTRuST Consortium to evaluate the
safety, tolerability and efficacy of oral ganaxolone after six
weeks of dosing in patients with PTSD. The INTRuST Consortium is a
group of clinical study centers in the United States funded by a
Department of Defense award to advance treatments and medical
research in PTSD and traumatic brain injury. This public-private
collaboration will study ganaxolone under Marinus’ Investigational
New Drug Application (IND) filed with the Food and Drug
Administration (FDA). The trial will take place in the United
States and is designed to enroll approximately 120 PTSD
patients.

“Ganaxolone has been shown in clinical studies to be efficacious
and well tolerated in refractory epilepsy patients, and we expect
the INTRuST PTSD trial to expand ganaxolone’s profile into
neurosteroid-mediated psychiatric disorders,” said Kenneth Shaw
Ph.D., Senior Vi

‘/>”/>

SOURCE

Related Articles Read More >

A rat holding its face with its paws
Ultrasound research with rats shows potential for depression therapy
Tivic Health CEO Jennifer Ernst
Sinus pain is just the beginning for Tivic Health’s CEO
A series of before-and-after brain scans showing improvement in long COVID patients after hyperbaric oxygen therapy
Long COVID study finds potential in hyperbaric oxygen therapy
microrobot-purdue-university
This microrobot device could remove brain hemorrhages caused by stroke

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech